<div id="readability-page-1"><p>Tufton Capital Management raised its position in shares of  Eli Lilly and Company (NYSE:LLY - Free Report) by 20.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor  owned 5,732 shares of the company's stock after buying an additional 986 shares during the period. Tufton Capital Management's holdings in Eli Lilly and Company were worth $4,373,000 as of its most recent filing with the Securities and Exchange Commission.</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><ul><li>3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026</li></ul><p>Several other institutional investors and hedge funds have also modified their holdings of LLY. Harvey Capital Management Inc. bought a new stake in shares of  Eli Lilly and Company during the third quarter worth $5,098,000.  Avantax Planning Partners Inc. raised its stake in shares of  Eli Lilly and Company by 8.3% during the third quarter. Avantax Planning Partners Inc. now owns 6,037 shares of the company's stock worth $4,606,000 after buying an additional 463 shares during the last quarter.  Sovran Advisors LLC lifted its holdings in  Eli Lilly and Company by 26.4% in the third quarter. Sovran Advisors LLC now owns 2,112 shares of the company's stock valued at $1,783,000 after buying an additional 441 shares during the period.  Patron Partners LLC boosted its stake in  Eli Lilly and Company by 30.0% in the third quarter. Patron Partners LLC now owns 5,158 shares of the company's stock valued at $3,936,000 after acquiring an additional 1,190 shares during the last quarter.  Finally, OneAscent Family Office LLC grew its holdings in  Eli Lilly and Company by 3.0% during the 3rd quarter. OneAscent Family Office LLC now owns 551 shares of the company's stock worth $420,000 after acquiring an additional 16 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of research analysts have recently weighed in on the company. Sanford C. Bernstein  reissued an &#34;outperform&#34; rating on shares of Eli Lilly and Company in a research note on Friday, December 19th. Guggenheim decreased their price target on shares of Eli Lilly and Company from $1,163.00 to $1,161.00 and set a &#34;buy&#34; rating for the company in a report on Tuesday, January 20th. Wells Fargo &amp; Company raised their price objective on Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the stock an &#34;overweight&#34; rating in a research note on Wednesday, December 10th. Wolfe Research boosted their target price on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an &#34;outperform&#34; rating in a research note on Wednesday, December 3rd. Finally, Jefferies Financial Group increased their price target on Eli Lilly and Company from $976.00 to $1,300.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, January 8th. Four investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued  a Hold rating to the company's stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of &#34;Buy&#34; and an average target price of $1,174.61.</p><ul><li>Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All</li></ul><p><b>Get Our Latest Analysis on Eli Lilly and Company</b></p><h2>Eli Lilly and Company Stock Performance</h2><p>Shares of NYSE LLY opened at $1,065.05 on Monday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The stock has a market capitalization of $1.01 trillion, a PE ratio of 52.11, a price-to-earnings-growth ratio of 0.80 and a beta of 0.35. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The stock has a 50 day moving average price of $1,057.19 and a 200 day moving average price of $881.44. </p><ul><li>A Fresh IPO That Long-Term Investors Shouldn’t Ignore</li></ul><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts' consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same period in the previous year, the company earned $1.18 earnings per share. The firm's revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS.  Analysts predict that  Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year. </p><h2>Eli Lilly and Company Increases Dividend</h2><p>The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. This is an increase from Eli Lilly and Company's previous quarterly dividend of $1.50. Eli Lilly and Company's dividend payout ratio  is presently 29.35%. </p><h2>Eli Lilly and Company Profile</h2> (Free Report)<p>Eli Lilly and Company <span>NYSE: LLY<span></span></span> is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.</p><h2>See Also</h2><ul><li>Five stocks we like better than Eli Lilly and Company</li><li>Refund From 1933: Trump’s Reset May Create Instant Wealth</li><li>Buy This Stock at 9:30 AM on MONDAY!</li><li>What Expenses Can Be Deducted From Capital Gains Tax?</li><li>Trump Planning to Use Public Law 63-43: Prepare Now</li><li>A U.S. “birthright” claim worth trillions - activated quietly</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Tufton Capital Management increased its stake in Eli Lilly and Company (NYSE: LLY) by 20.8% in Q3, acquiring an additional 986 shares, bringing its total to 5,732 shares valued at $4.37 million. Other institutional investors also adjusted their holdings, with significant increases from Harvey Capital Management and Patron Partners. Analysts maintain a positive outlook on Eli Lilly, with a consensus rating of "Buy" and an average target price of $1,174.61. The stock opened at $1,065.05, with a market cap of $1.01 trillion and a recent earnings report showing strong performance.</p>

Market Beat

Eli Lilly

ALPS Medical Breakthrough

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

Direxion Daily LLY Bear 1X Shares

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

iShares US Pharma

Health Care Select Sector SPDR

VG Health

iShares Biotechnology ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Direxion Daily LLY Bull 2X Shares

Defiance Daily Target 2X Long LLY ETF

iShares Global Healthcare

Tufton Capital Management Purchases 986 Shares of Eli Lilly and Company $LLY